Shitara K, et al. - The safety, tolerability, pharmacokinetics, and tumor response of ramucirumab were evaluated in combination with 1 of 3 platinum/fluoropyrimidine regimens among Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. In combination with capecitabine + cisplatin (XP), S-1 + cisplatin (SP), or S-1 + oxaliplatin (SOX), ramucirumab 8 mg/kg on days 1 and 8 every 3 weeks was generally well tolerated and showed preliminary anti-tumor activity among these patients.